Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New mycoplasma and respiratory syncytial virus (RSV) assays from Gamidor (UK):

This article was originally published in Clinica

Executive Summary

Gamidor (UK) has introduced two mycoplasma antibody assays for human serum testing. SeroELISA Mp has a dual use, says the company: to determine IgM antibodies for early diagnosis, or to show the rise of total immunoglobulins in paired sera taken 7-14 days apart, providing diagnosis of current infection. SeroELISA Mp-IgM, specific for IgM antibodies, is suitable for early diagnosis and determining recent infections. Both assays are suitable for automation. Gamidor has also introduced Directgen RSV, a rapid, credit card-style STAT assay for respiratory virus antigen in nasopharyngeal washes, aspirates or swab samples. The assay offers 93-97% sensitivity and 90-97% specificity, and results are available in about six minutes, Gamidor says.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094016

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel